AGIOS PHARMACEUTICALS, INC.

Lobbying client · Massachusetts · filed 2025 to 2026

rare disease focused biopharmaceutical company

$30,000 Reported spend

4 Filings counted

1 Firms hired

0 Bills named

Spend is reported income plus in-house expenses across 4 filings. Everything on this page is grouped by the client's LDA id (70491), not by name.

Firms hired 1

JEFFREY J. KIMBELL & ASSOCIATES, INC. $30,000 4 filings

Reported by year 2 years

2026 $20,000 2 filings
2025 $10,000 2 filings

Issues lobbied 1

Health Issues 4

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

Agencies and chambers lobbied 2

HOUSE OF REPRESENTATIVES 3
SENATE 3

Recent filings 4 total

Q2

JEFFREY J. KIMBELL & ASSOCIATES, INC.

2nd Quarter (Apr 1 - June 30) 2026 · House · Senate · $10,000 income · posted Jul 20, 2026

View → Q1

JEFFREY J. KIMBELL & ASSOCIATES, INC.

1st Quarter (Jan 1 - Mar 31) 2026 · House · Senate · $10,000 income · posted Apr 20, 2026

View → Q4

JEFFREY J. KIMBELL & ASSOCIATES, INC.

4th Quarter (Oct 1 - Dec 31) 2025 · House · Senate · $10,000 income · posted Jan 20, 2026

View → RR

JEFFREY J. KIMBELL & ASSOCIATES, INC.

4th Quarter (Oct 1 - Dec 31) 2025 · posted Jan 9, 2026

View →

Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.